Adipose-tissue and intestinal inflammation - visceral obesity and creeping fat

Frontiers in Immunology

Volumn 5, Issue SEP, 2014, Pages

  Kredel, Lea I ^a   Siegmund, Britta ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adipose tissue; Adipose tissue inflammation; Crohn's disease; Intestinal inflammation; Obesity

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; LEPTIN;

ADIPOSE TISSUE; BIOACCUMULATION; CHRONIC INFLAMMATION; CROHN DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; ENTERITIS; GENE EXPRESSION; GRANULOCYTE; HELPER CELL; HUMAN; HYPERPLASIA; HYPERTENSION; HYPERTROPHY; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INTRAABDOMINAL FAT; LIPID STORAGE; LYMPHOID CELL; MACROPHAGE; NATURAL KILLER T CELL; NONHUMAN; OBESITY; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 84919417429     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00462     Document Type: Review

References (153)

1. Buchwald H. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis (2005) 1(3):371-81. doi: 10.1016/j.soard.2005.04.002
2. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet (2012) 377(9765):557-67. doi:10.1016/S0140-6736(10)62037-5
3. Barness LA, Opitz JM, Gilbert-Barness E. Obesity: genetic, molecular, and environmental aspects. Am J Med Genet A (2007) 143A(24):3016-34. doi:10.1002/ajmg.a.32035
4. Haslam DW, James WP. Obesity. Lancet (2005) 366(9492):1197-209. doi:10.1016/S0140-6736(05)67483-1
5. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol (2009) 6(6):399-409. doi:10.1038/nrcardio.2009.55
6. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol (2011) 29:415-45. doi:10.1146/annurev-immunol-031210-101322
7. Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med (2013) 34(1):1-11. doi:10.1016/j.mam.2012.10.001
8. Vohl MC, Sladek R, Robitaille J, Gurd S, Marceau P, Richard D, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res (2004) 12(8):1217-22. doi:10.1038/oby.2004.153
9. Tchkonia T, Tchoukalova YD, Giorgadze N, Pirtskhalava T, Karagiannides I, Forse RA, et al. Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am J Physiol Endocrinol Metab (2005) 288(1):E267-77. doi:10.1152/ajpendo.00265.2004
10. Gesta S, Bluher M, Yamamoto Y, Norris AW, Berndt J, Kralisch S, et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci U S A (2006) 103(17):6676-81. doi:10.1073/pnas.0601752103
11. Deiuliis J, Shah Z, Shah N, Needleman B, Mikami D, Narula V, et al. Visceral adipose inflammation in obesity is associated with critical alterations in tregulatory cell numbers. PLoS One (2011) 6(1):e16376. doi:10.1371/journal.pone.0016376
12. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology (2004) 145(5):2273-82. doi:10.1210/en.2003-1336
13. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol (2008) 28(7):1304-10. doi:10.1161/ATVBAHA.108.165100
14. Rocha VZ, Folco EJ. Inflammatory concepts of obesity. Int J Inflam (2011) 2011:529061. doi:10.4061/2011/529061
15. Barbarroja N, Lopez-Pedrera R, Mayas MD, Garcia-Fuentes E, Garrido-Sanchez L, Macias-Gonzalez M, et al. The obese healthy paradox: is inflammation the answer? Biochem J (2010) 430(1):141-9. doi:10.1042/BJ20100285
16. Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G, et al. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care (2009) 32(5):932-7. doi:10.2337/dc08-1856
17. Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev (2006) 27(5):449-67. doi:10.1210/er.2005-0022
18. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, Beclin E, Decourcelle C, Antunes L, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut (2007) 56(4):577-83. doi:10.1136/gut.2005.082925
19. Sheehan AL, Warren BF, Gear MW, Shepherd NA. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg (1992) 79(9):955-8. doi:10.1002/bjs.1800790934
20. Fink C, Karagiannides I, Bakirtzi K, Pothoulakis C. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis (2012) 18(8):1550-7. doi:10.1002/ibd.22893
21. Drouet M, Dubuquoy L, Desreumaux P, Bertin B. Visceral fat and gut inflammation. Nutrition (2012) 28(2):113-7. doi:10.1016/j.nut.2011.09.009
22. Paul G, Schaffler A, Neumeier M, Furst A, Bataillle F, Buechler C, et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis (2006) 12(6):471-7. doi:10.1097/00054725-200606000-00005
23. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, Rousseaux C, Dubuquoy C, Decourcelle C, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut (2012) 61(1):78-85. doi:10.1136/gutjnl-2011-300370
24. Batra A, Heimesaat MM, Bereswill S, Fischer A, Glauben R, Kunkel D, et al. Mesenteric fat - control site for bacterial translocation in colitis? Mucosal Immunol (2012) 5(5):580-91. doi:10.1038/mi.2012.33
25. Pond CM. Adipose tissue and the immune system. Prostaglandins Leukot Essent Fatty Acids (2005) 73(1):17-30. doi:10.1016/j.plefa.2005.04.005
26. Zulian A, Cancello R, Ruocco C, Gentilini D, Di Blasio AM, Danelli P, et al. Differences in visceral fat and fat bacterial colonization between ulcerative colitis and Crohn's disease. An in vivo and in vitro study. PLoS One (2013) 8(10):e78495. doi:10.1371/journal.pone.0078495
27. Tanabe T, Chamaillard M, Ogura Y, Zhu L, Qiu S, Masumoto J, et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J (2004) 23(7):1587-97. doi:10.1038/sj.emboj.7600175
28. Gutierrez A, Scharl M, Sempere L, Holler E, Zapater P, Almenta I, et al. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut (2014) 63(2):272-80. doi:10.1136/gutjnl-2012-303557
29. Park A, Kim WK, Bae KH. Distinction of white, beige and brown adipocytes derived from mesenchymal stem cells. World J Stem Cells (2014) 6(1):33-42. doi:10.4252/wjsc.v6.i1.33
30. Rosenwald M, Wolfrum C. The origin and definition of brite versus white and classical brown adipocytes. Adipocyte (2014) 3(1):4-9. doi:10.4161/adip.26232
31. Giordano A, Smorlesi A, Frontini A, Barbatelli G, Cinti S. White, brown and pink adipocytes: the extraordinary plasticity of the adipose organ. Eur J Endocrinol (2014) 170(5):R159-71. doi:10.1530/EJE-13-0945
32. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell (2014) 156(1-2):20-44. doi:10.1016/j.cell.2013.12.012
33. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab (2007) 92(3):1023-33. doi:10.1210/jc.2006-1055
34. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab (2005) 19(4):471-82. doi:10.1016/j.beem.2005.07.004
35. Zulian A, Cancello R, Micheletto G, Gentilini D, Gilardini L, Danelli P, et al. Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? Gut (2012) 61(1):86-94. doi:10.1136/gutjnl-2011-300391
36. Kopp A, Buechler C, Bala M, Neumeier M, Scholmerich J, Schaffler A. Toll-like receptor ligands cause proinflammatory and prodiabetic activation of adipocytes via phosphorylation of extracellular signal-regulated kinase and c-Jun N-terminal kinase but not interferon regulatory factor-3. Endocrinology (2010) 151(3):1097-108. doi:10.1210/en.2009-1140
37. Weber M, Sporrer D, Weigert J, Wanninger J, Neumeier M, Wurm S, et al. Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes. FEBS Lett (2009) 583(22):3718-24. doi:10.1016/j.febslet.2009.10.008
38. Batra A, Zeitz M, Siegmund B. Adipokine signaling in inflammatory bowel disease. Inflamm Bowel Dis (2009) 15(12):1897-905. doi:10.1002/ibd.20937
39. Mustain WC, Starr ME, Valentino JD, Cohen DA, Okamura D, Wang C, et al. Inflammatory cytokine gene expression in mesenteric adipose tissue during acute experimental colitis. PLoS One (2013) 8(12):e83693. doi:10.1371/journal.pone.0083693
40. Thomaz MA, Acedo SC, de Oliveira CC, Pereira JA, Priolli DG, Saad MJ, et al. Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. Pharmacol Res (2009) 60(4):341-6. doi:10.1016/j.phrs.2009.05.003
41. Gambero A, Marostica M, Abdalla Saad MJ, Pedrazzoli J Jr. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis (2007) 13(11):1357-64. doi:10.1002/ibd.20222
42. Olivier I, Theodorou V, Valet P, Castan-Laurell I, Guillou H, Bertrand-Michel J, et al. Is Crohn's creeping fat an adipose tissue? Inflamm Bowel Dis (2011) 17(3):747-57. doi:10.1002/ibd.21413
43. Olivier I, Theodorou V, Valet P, Castan-Laurell I, Ferrier L, Eutamene H. Modifications of mesenteric adipose tissue during moderate experimental colitis in mice. Life Sci (2014) 94(1):1-7. doi:10.1016/j.lfs.2013.09.028
44. Gimble JM, Bunnell BA, Frazier T, Rowan B, Shah F, Thomas-Porch C, et al. Adipose-derived stromal/stem cells: a primer. Organogenesis (2013) 9(1):3-10. doi:10.4161/org.24279
45. Mantovani A, Locati M. Orchestration of macrophage polarization. Blood (2009) 114(15):3135-6. doi:10.1182/blood-2009-07-231795
46. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci (2008) 13:453-61. doi:10.2741/2692
47. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol (2014) 14(6):392-404. doi:10.1038/nri3671
48. Morris DL, Singer K, Lumeng CN. Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr Metab Care (2011) 14(4):341-6. doi:10.1097/MCO.0b013e328347970b
49. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest (2007) 117(1):175-84. doi:10.1172/JCI29881
50. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) (2007) 31(9):1420-8. doi:10.1038/sj.ijo.0803632
51. Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett (2007) 112(2):61-7. doi:10.1016/j.imlet.2007.07.003
52. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 112(12):1796-808. doi:10.1172/JCI19246
53. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 112(12):1821-30. doi:10.1172/JCI19451
54. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol (2010) 72:219-46. doi:10.1146/annurev-physiol-021909-135846
55. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm (2010) 2010:513948. doi:10.1155/2010/513948
56. Fain JN, Bahouth SW, Madan AK. TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord (2004) 28(4):616-22. doi:10.1038/sj.ijo.0802594
57. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes (2005) 54(8):2277-86. doi:10.2337/diabetes.54.8.2277
58. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes (2006) 55(6):1554-61. doi:10.2337/db06-0133
59. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol (2011) 11(11):738-49. doi:10.1038/nri3071
60. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest (2006) 116(1):33-5. doi:10.1172/JCI27280
61. Carvalheira JB, Qiu Y, Chawla A. Blood spotlight on leukocytes and obesity. Blood (2013) 122(19):3263-7. doi:10.1182/blood-2013-04-459446
62. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest (2006) 116(7):1793-801. doi:10.1172/JCI29069
63. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) (2006) 30(9):1347-55. doi:10.1038/sj.ijo.0803259
64. Inouye KE, Shi H, Howard JK, Daly CH, Lord GM, Rollins BJ, et al. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes (2007) 56(9):2242-50. doi:10.2337/db07-0425
65. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest (2006) 116(1):115-24. doi:10.1172/JCI24335C1
66. Kitade H, Sawamoto K, Nagashimada M, Inoue H, Yamamoto Y, Sai Y, et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes (2012) 61(7):1680-90. doi:10.2337/db11-1506
67. Kim D, Kim J, Yoon JH, Ghim J, Yea K, Song P, et al. CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice. Diabetologia (2014) 57(7):1456-65. doi:10.1007/s00125-014-3237-5
68. Nagareddy PR, Kraakman M, Masters SL, Stirzaker RA, Gorman DJ, Grant RW, et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab (2014) 19(5):821-35. doi:10.1016/j.cmet.2014.03.029
69. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev (2013) 93(1):1-21. doi:10.1152/physrev.00017.2012
70. Dalmas E, Clement K, Guerre-Millo M. Defining macrophage phenotype and function in adipose tissue. Trends Immunol (2011) 32(7):307-14. doi:10.1016/j.it.2011.04.008
71. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science (2011) 332(6035):1284-8. doi:10.1126/science.1204351
72. Haase J, Weyer U, Immig K, Kloting N, Bluher M, Eilers J, et al. Local proliferation of macrophages in adipose tissue during obesity-induced inflammation. Diabetologia (2014) 57(3):562-71. doi:10.1007/s00125-013-3139-y
73. Amano SU, Cohen JL, Vangala P, Tencerova M, Nicoloro SM, Yawe JC, et al. Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell Metab (2014) 19(1):162-71. doi:10.1016/j.cmet.2013.11.017
74. Oh HJ, Park EJ, Lee SY, Soh JW, Kong IS, Choi SW, et al. Comparison of cell proliferation and epigenetic modification of gene expression patterns in canine foetal fibroblasts and adipose tissue-derived mesenchymal stem cells. Cell Prolif (2012) 45(5):438-44. doi:10.1111/j.1365-2184.2012.00838.x
75. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes (2008) 57(12):3239-46. doi:10.2337/db08-0872
76. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res (2005) 46(11):2347-55. doi:10.1194/jlr.M500294-JLR200
77. Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, Basdevant A, et al. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab (2009) 94(11):4619-23. doi:10.1210/jc.2009-0925
78. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J (2004) 18(14):1657-69. doi:10.1096/fj.04-2204com
79. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, et al. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab (2010) 299(6):E1016-27. doi:10.1152/ajpendo.00329.2010
80. Fjeldborg K, Pedersen SB, Moller HJ, Christiansen T, Bennetzen M, Richelsen B. Human adipose tissue macrophages are enhanced but changed to an anti-inflammatory profile in obesity. J Immunol Res (2014) 2014:309548. doi:10.1155/2014/309548
81. Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, et al. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes (2010) 59(7):1648-56. doi:10.2337/db09-0287
82. Kredel LI, Batra A, Stroh T, Kuhl AA, Zeitz M, Erben U, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn's disease. Gut (2012) 62(6):852-62. doi:10.1136/gutjnl-2011-301424
83. Lovren F, Pan Y, Quan A, Szmitko PE, Singh KK, Shukla PC, et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol (2010) 299(3):H656-63. doi:10.1152/ajpheart.00115.2010
84. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science (2011) 332(6026):243-7. doi:10.1126/science.1201475
85. Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, Hatano B, et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab (2008) 7(6):485-95. doi:10.1016/j.cmet.2008.04.002
86. Lee SD, Tontonoz P. Eosinophils in fat: pink is the new brown. Cell (2014) 157(6):1249-50. doi:10.1016/j.cell.2014.05.025
87. Talukdar S, Oh da Y, Bandyopadhyay G, Li D, Xu J, McNelis J, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med (2012) 18(9):1407-12. doi:10.1038/nm.2885
88. Hams E, Locksley RM, McKenzie AN, Fallon PG. Cutting edge: IL-25 elicits innate lymphoid type 2 and type II NKT cells that regulate obesity in mice. J Immunol (2013) 191(11):5349-53. doi:10.4049/jimmunol.1301176
89. Molofsky AB, Nussbaum JC, Liang HE, Van Dyken SJ, Cheng LE, Mohapatra A, et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med (2013) 210(3):535-49. doi:10.1084/jem.20121964
90. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells - how did we miss them? Nat Rev Immunol (2013) 13(2):75-87. doi:10.1038/nri3349
91. Lanier LL. Shades of grey - the blurring view of innate and adaptive immunity. Nat Rev Immunol (2013) 13(2):73-4. doi:10.1038/nri3389
92. Bernink J, Mjosberg J, Spits H. Th1- and Th2-like subsets of innate lymphoid cells. Immunol Rev (2013) 252(1):133-8. doi:10.1111/imr.12034
93. Spits H. Group 2 innate lymphoid cells show up in the skin. Immunol Cell Biol (2013) 91(6):390-2. doi:10.1038/icb.2013.24
94. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol (2013) 13(2):145-9. doi:10.1038/nri3365
95. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 172(3):1455-62. doi:10.4049/jimmunol.172.3.1455
96. Basu S, Eriksson M, Pioli PA, Conejo-Garcia J, Mselle TF, Yamamoto S, et al. Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs. Am J Reprod Immunol (2009) 61(1):52-61. doi:10.1111/j.1600-0897.2008.00661.x
97. Duffaut C, Galitzky J, Lafontan M, Bouloumie A. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun (2009) 384(4):482-5. doi:10.1016/j.bbrc.2009.05.002
98. O'Rourke RW, Gaston GD, Meyer KA, White AE, Marks DL. Adipose tissue NK cells manifest an activated phenotype in human obesity. Metabolism (2013) 62(11):1557-61. doi:10.1016/j.metabol.2013.07.011
99. Lynch L. Adipose invariant natural killer T cells. Immunology (2014) 142(3):337-46. doi:10.1111/imm.12269
100. Watarai H, Sekine-Kondo E, Shigeura T, Motomura Y, Yasuda T, Satoh R, et al. Development and function of invariant natural killer T cells producing T(h)2- and T(h)17-cytokines. PLoS Biol (2012) 10(2):e1001255. doi:10.1371/journal.pbio.1001255
101. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol (2013) 13(2):101-17. doi:10.1038/nri3369
102. Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity (2012) 37(3):574-87. doi:10.1016/j.immuni.2012.06.016
103. Schipper HS, Rakhshandehroo M, van de Graaf SF, Venken K, Koppen A, Stienstra R, et al. Natural killer T cells in adipose tissue prevent insulin resistance. J Clin Invest (2012) 122(9):3343-54. doi:10.1172/JCI62739
104. Schipper HS, Prakken B, Kalkhoven E, Boes M. Adipose tissue-resident immune cells: key players in immunometabolism. Trends Endocrinol Metab (2012) 23(8):407-15. doi:10.1016/j.tem.2012.05.011
105. Ji YS, Xu A, Bhargava P, Yang L, Lam KS, Gao B, et al. Activation of natural killer T'cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via -4 (IL-4)/STAT6 protein signaling axis in obesity. J Biol Chem (2012) 287(17):13561-71. doi:10.1074/jbc.M112.350066
106. Ji YS, Xia S, Yang L, Li X, Qi L. Short term high fat diet challenge promotes alternative macrophage polarization in adipose tissue via natural killer T cells and interleukin-42012. J Biol Chem (2012) 287(29):24378-86. doi:10.1074/jbc.M112.371807
107. Martin-Murphy BV, You Q, Wang H, De La Houssaye BA, Reilly TP, Friedman JE, et al. Mice lacking natural killer T cells are more susceptible to metabolic alterations following high fat diet feeding. PLoS One (2014) 9(1):e80949. doi:10.1371/journal.pone.0080949
108. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med (2009) 15(8):930-9. doi:10.1038/nm.2002
109. Duffaut C, Zakaroff-Girard A, Bourlier V, Decaunes P, Maumus M, Chiotasso P, et al. Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators. Arterioscler Thromb Vasc Biol (2009) 29(10):1608-14. doi:10.1161/ATVBAHA.109.192583
110. O'Rourke RW, Metcalf MD, White AE, Madala A, Winters BR, Maizlin II, et al. Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue. Int J Obes (Lond) (2009) 33(9):978-90. doi:10.1038/ijo.2009.133
111. Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation (2007) 115(8):1029-38. doi:10.1161/CIRCULATIONAHA.106.638379
112. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 15(8):921-9. doi:10.1038/nm.2001
113. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol (2009) 10(7):689-95. doi:10.1038/ni.1760
114. Cipolletta D. Adipose tissue-resident regulatory T cells: phenotypic specialization, functions and therapeutic potential. Immunology (2014) 142(4):517-25. doi:10.1111/imm.12262
115. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature (2012) 486(7404):549-53. doi:10.1038/nature11132
116. Cipolletta D, Kolodin D, Benoist C, Mathis D. Tissular T(regs): a unique population of adipose-tissue-resident Foxp3+CD4+ T cells that impacts organismal metabolism. Semin Immunol (2011) 23(6):431-7. doi:10.1016/j.smim.2011.06.002
117. Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A (2010) 107(21):9765-70. doi:10.1073/pnas.0908771107
118. Zeyda M, Huber J, Prager G, Stulnig TM. Inflammation correlates with markers of T-cell subsets including regulatory T cells in adipose tissue from obese patients. Obesity (Silver Spring) (2010) 19(4):743-8. doi:10.1038/oby.2010.123
119. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev (2014) 13(1):3-10. doi:10.1016/j.autrev.2013.06.004
120. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology (2005) 128(7):1868-78. doi:10.1053/j.gastro.2005.03.043
121. Wang Y, Liu XP, Zhao ZB, Chen JH, Yu CG. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. J Dig Dis (2011) 12(4):286-94. doi:10.1111/j.1751-2980.2011.00505.x
122. Lee YK, Mukasa R, Hatton RD, Weaver CT. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol (2009) 21(3):274-80. doi:10.1016/j.coi.2009.05.021
123. Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS, et al. Differential regulation of - 17 and interferon gamma production in inflammatory bowel disease. Gut (2009) 58(12):1629-36. doi:10.1136/gut.2009.182170
124. Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One (2010) 5(8):e12191. doi:10.1371/journal.pone.0012191
125. Lam YY, Ha CW, Campbell CR, Mitchell AJ, Dinudom A, Oscarsson J, et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One (2012) 7(3):e34233. doi:10.1371/journal.pone.0034233
126. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palu G, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2007) 292(2):G518-25. doi:10.1152/ajpgi.00024.2006
127. Ungar B, Kopylov U, Goitein D, Lahat A, Bardan E, Avidan B, et al. Severe and morbid obesity in Crohn's disease patients: prevalence and disease associations. Digestion (2013) 88(1):26-32. doi:10.1159/000351529
128. Mendall MA, Gunasekera AV, John BJ, Kumar D. Is obesity a risk factor for Crohn's disease? Dig Dis Sci (2011) 56(3):837-44. doi:10.1007/s10620-010-1541-6
129. Max JB, Stidham R, Su GL, Waljee AK. Obesity and IBD: are we tipping the scales toward an epidemic? Gastroenterology (2013) 145(2):478-9. doi:10.1053/j.gastro.2013.06.020
130. Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn's disease clinical course and severity in obese patients. Clin Nutr (2002) 21(1):51-7. doi:10.1054/clnu.2001.0503
131. Nascimento AT, Rocha R, Coqueiro FG, Santana GO, Lyra AC. Does obesity complicate inflammatory bowel diseases? J Crohns Colitis (2014) 6(10):1041. doi:10.1016/j.crohns.2012.06.008
132. Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol (2006) 4(4):482-8. doi:10.1016/j.cgh.2005.12.015
133. Causey MW, Johnson EK, Miller S, Martin M, Maykel J, Steele SR. The impact of obesity on outcomes following major surgery for Crohn's disease: an American College of Surgeons National Surgical Quality Improvement Program assessment. Dis Colon Rectum (2011) 54(12):1488-95. doi:10.1097/DCR.0b013e3182342ccb
134. Long MD, Crandall WV, Leibowitz IH, Duffy L, del Rosario F, Kim SC, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis (2011) 17(10):2162-8. doi:10.1002/ibd.21585
135. Zwintscher NP, Horton JD, Steele SR. Obesity has minimal impact on clinical outcomes in children with inflammatory bowel disease. J Pediatr Surg (2014) 49(2):265-8; discussion 8. doi:10.1016/j.jpedsurg.2013.11.033
136. Bhalme MS, Sharma A, Keld R, Willert R, Campbell S. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease? Eur J Gastroenterol Hepatol (2013) 25(5):543-9. doi:10.1097/MEG.0b013e32835d1f15
137. Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 19(10):2118-24. doi:10.1097/MIB.0b013e31829cf401
138. Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, et al. Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatology (Oxford) (2014) 53(5):875-81. doi:10.1093/rheumatology/ket433
139. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol (2011) 106(4):563-73. doi:10.1038/ajg.2011.44
140. Gruber L, Kisling S, Lichti P, Martin FP, May S, Klingenspor M, et al. High fat diet accelerates pathogenesis of murine Crohn's disease-like ileitis independently of obesity. PLoS One (2013) 8(8):e71661. doi:10.1371/journal.pone.0071661
141. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature (2012) 487(7405):104-8. doi:10.1038/nature11225
142. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev (2000) 21(6):697-738. doi:10.1210/edrv.21.6.0415
143. Lee M-J, Fried SK. Depot-specific biology of adipose tissues: links to fat distribution and metabolic risk. In: Leff T, Granneman JG, editors. Adipose Tissue in Health and Disease. Weinheim: Wiley-VCH Verlag GmbH & Co (2010). p. 283-306.
144. Patel P, Abate N. Body fat distribution and insulin resistance. Nutrients (2013) 5(6):2019-27. doi:10.3390/nu5062019
145. Berryman DE, Glad CA, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Immunol (2013) 9(6):346-56. doi:10.1038/nrendo.2013.64
146. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab (2002) 87(12):5662-7. doi:10.1210/jc.2002-020635
147. Freedland ES. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab (2004) 1(1):12. doi:10.1186/1743-7075-1-12
148. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta (2000) 1500(1):88-96. doi:10.1016/S0925-4439(99)00091-5
149. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation (2007) 116(11):1234-41. doi:10.1161/CIRCULATIONAHA.107.710509
150. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab (1998) 83(11):3925-9. doi:10.1210/jc.83.11.3925
151. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab (2005) 90(4):2282-9. doi:10.1210/jc.2004-1696
152. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev (2010) 11(1):11-8. doi:10.1111/j.1467-789X.2009.00623.x
153. Ferrer-Lorente R, Bejar MT, Badimon L. Notch signaling pathway activation in normal and hyperglycemic rats differs in the stem cells of visceral and subcutaneous adipose tissue. Stem Cells Dev (2014). doi:10.1089/scd.2014.0070